Recently, good news about CAR-T cell immunotherapy technology continues: At the end of March, Novartis's CAR-T therapy CTL019 has obtained the priority review qualification issued by the US FDA, and is expected to be listed in the near future to treat relapsed or refractory children or young people. Sexual acute B-cell lymphoid leukemia. On April 19th, CTL019 received a breakthrough therapy from the US FDA to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL). At the same time, other CARs abroad -T companies have also submitted relevant applications. In order to further analyze the domestic CAR-T industry research trends, the domestic future CAR-T supervision mode and the future operation mode, the “CAR-T Industry Special Event Second Station-Jike Gene Experts Offline Sharing Meeting†initiated by Industrial Securities was 4 Held in the Jikai Gene Report Hall on the 19th. At the sharing meeting, Industrial Securities invited General Manager Yu Xuejun, the head of the Jikai Gene CAR-T project, and Dr. Zeng Li, Assistant President of Jikai Gene, on CAR-T domestic research trends, clinical trials, regulatory models, future operating models and possible The international competition situation has been analyzed and discussed. The event attracted people from Fangyuan Capital, Tonghe Capital, Sanjiang Capital, Yongzheng Investment, Jujin Investment, Fuhou Venture Capital, Jinbang Capital, Zhengxiang Investment, Caijin Capital, Binghong Capital, Yuanxing Capital. More than 40 investment institutions and securities analysis institutions such as Oriental Fortune, Phoenix Investment, Borun Investment, Dongfang Securities, and Industrial Securities, as well as some biotechnology companies. General Manager Yu Xuejun, Head of Jikai Gene CAR-T Project At present, the country has basically confirmed that CAR-T cell therapy should be carried out in accordance with the drug regulatory model (Draft Comment Draft, December 16, 2016). At the request of Xingye Securities, Jikai Gene carried out the exchange meeting, adhering to the mentality of open cooperation, sharing with everyone the experience gained by Jike Gene in the work related to CAR-T cell therapy, and the future direction of CAR-T R&D dynamics, regulatory models and future industrialization routes are open and honest with participants. Jikai Gene started the CAR-T project in November 2014. After introducing the various tasks carried out by the project, General Manager Yu invited the representatives of the participating companies to visit the Jikai Gene “GMP Genetic Engineering Carrier Production Workshop†and "GMP Engineered Cell Preparation Center." Among the delegates, many were representatives of institutions familiar with the domestic CAR-T industry. After visiting the two GMP production centers of the Jikai Gene CAR-T industry, they worked on the Jikai gene in the CAR-T field. I am deeply shocked; I also have a deep understanding of the Jikai gene's strict control of "drug safety" and "product consistency" in CAR-T clinical trials. The results are often used to detect disease. Gastric acidity pH is 3.5 ~ 7.0, common in atrophic gastritis, gastric cancer, secondary iron deficiency anemia, gastric dilatation, hyperthyroidism. Reduced gastric acidity is seen in duodenal reflux, gastric ulcer, gastric cancer, atrophic gastritis, chronic gastritis, pernicious anemia, etc. Such as duodenal bulb ulcer, Zhu-Ai syndrome, pyloric obstruction, chronic cholecystitis, duodenal fluid reflux will also increase pH. Gastric Acid Ph Test Strips,Gastric Acid Strips,Gastric Acid Test Strips,Gastric Acid Ph Strips,Gastric Acid Ph Test Kits,Gastric Acid Ph Test Paper Changchun LYZ Technology Co., Ltd , https://www.lyzstrips.com
normal
PH0.9 ~ 1.8.
Clinical significance of test results
(1) Gastric acid reduction: pH3.5 ~ 7.0, common in atrophic gastritis, gastric cancer, secondary iron deficiency anemia, gastric dilatation, hyperthyroidism. Reduced gastric acidity is seen in duodenal reflux, gastric ulcer, gastric cancer, atrophic gastritis, chronic gastritis, pernicious anemia, etc.
(2) Increased gastric acidity: in duodenal bulb ulcer, Zhuo-Ai syndrome, pyloric obstruction, chronic cholecystitis, duodenal fluid reflux will also increase pH.
Analyze the business model of CAR-T treatment under different regulatory models